Publication #7188

Reference
CEM_CMO(2020)042
Name
COVID-19 therapeutic alert – Therapeutic Anticoagulation (Heparin) in the Management of Severe COVID-19 (SARS-CoV-2 Positive) Patients
Categories
Scottish Government CMO Letters
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS SCOTLAND COVID-19 CORONAVIRUS TREATMENTS DRUGS
Description
Therapeutic dose of either unfractionated heparin (UFH) or subcutaneous low molecular weight heparin (LMWH) should not be offered in the treatment of patients with COVID-19, unless there is a standard indication for therapeutic anti-coagulation, such as the acute management of acute deep vein thromboses or pulmonary emboli, or as part of a clinical trial. Continue to use pharmacological VTE prophylaxis in COVID-19 pneumonia, unless contraindicated, with a standard prophylactic dose (for acutely ill medical patients) of low molecular weight heparin (LMWH).

Contact Name
Irene Fazakerley
Contact Address
Chief Medical Officer Directorate Pharmacy and Medicines Division St Andrew’s House Regent Road Edinburgh EH1 3DG
Contact Phone

Created
2020-12-23 00:00:00


Click to go back to homepage